PD-1inhibitor is named as a drug or biological intervention in 4 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2), Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) and Shanghai Chest Hospital (1). Registered phases: Phase 3, Observational, Phase 1/2 and Phase 2. Conditions studied include HNSCC; Radiotherapy; PD-1.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05980715 | PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (ClinicalTrials.gov ↗) HNSCC, Radiotherapy, PD-1 |
Phase 3 | Recruiting |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer |
Phase 1/2 | Recruiting |
| NCT06417892 | Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma (ClinicalTrials.gov ↗) Gastric Cancer |
Observational | Recruiting |
| NCT07090707 | PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) (ClinicalTrials.gov ↗) HNSCC, PD-1, Radiotherapy |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| HNSCC | 2 |
| Radiotherapy | 2 |
| PD-1 | 2 |
| Gastric Cancer | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Unresectable Locally Advanced Esophageal Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Shanghai Chest Hospital | 1 |
| Register | PD-1inhibitor trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PD-1inhibitor works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PD-1inhibitor (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.